• Upstream Bio set pivotal Phase 3 plans for verekitug in severe asthma, CRSwNP, using 400 mg subcutaneous dosing every 12 weeks.
• One placebo-controlled Phase 3 trial planned per indication, totaling about 1,500 patients across both studies.
• Enrollment to include broad populations without baseline biomarker restrictions, targeting differentiated quarterly at-home administration.
• Trials targeted to start in Q1 2027, positioning for potential FDA BLA filings in both indications.
• Supportive Phase 3 results could enable a launch as early as 2030.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Upstream Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-377485), on September 01, 2026, and is solely responsible for the information contained therein.